In CLL, there are an estimated 1–7 × 104 ROR1 molecules on the surface, which is 10–100 folds lower than the conventional targets of monoclonal antibody (mAb) therapies. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.